ProShare Advisors
ANIK icon

ProShare Advisors’s Anika Therapeutics ANIK Stock Holding History

ProShare Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-6,097
Closed -$224K – 1976
2014
Q3 		$224K Sell
6,097
-1,404
-19% -$60.7K ﹤0.01% 1904
2014
Q2 		$348K Sell
7,501
-4,906
-40% -$218K ﹤0.01% 1807
2014
Q1 		$510K Buy
+12,407
New +$461K 0.01% 1851

Other funds holding ANIK

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
TSW
Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.58B AUM 51% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
GAM
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return

ProShare Advisors's ANIK Position: Q4 2014 in Review

ProShare Advisors sold out of Anika Therapeutics (ANIK) in Q4 2014, closing a stake of 6,097 shares — an estimated $224K sold.

ProShare Advisors first reported a position in ANIK in Q1 2014 and held it in 3 quarters. The position peaked at $510K in Q1 2014. 160 funds tracked by Wall St. Rank hold ANIK as of Q4 2014.

  • ProShare Advisors reported no remaining Anika Therapeutics position as of Q4 2014 after selling out during the quarter.
  • ProShare Advisors sold 6,097 Anika Therapeutics shares in Q4 2014, an estimated $224K.
  • ProShare Advisors first reported a position in Anika Therapeutics in Q1 2014 and held it in 3 quarters.
  • ProShare Advisors's Anika Therapeutics position peaked at $510K in Q1 2014.
  • 160 funds tracked by Wall St. Rank held Anika Therapeutics as of Q4 2014.

Based on ProShare Advisors's 13F filing for Q4 2014, filed 30 Jan 2015.